President and Chief Executive Officer — Jay S. Duker, M.D. Chief Financial Officer — George O. Elston Chief Medical Officer — Ramiro Ribeiro, M.D. Management expects DuraVu to be the only tyrosine ...

EyePoint Pharmaceuticals (NASDAQ:EYPT) used a presentation at the Guggenheim Emerging Biotech Emerging Outlook Biotech Summit 2026 to outline upcoming clinical catalysts for its lead retinal program, ...

– Phase 3 LUGANO and LUCIA clinical trials for DURAVYU ™ in wet AMD fully enrolled and on track for data readout beginning in mid-2026 – – Announced initiation of pivotal Phase 3 DME program ...

Top line data for DURAVYU in wet AMD (LUGANO and LUCIA trials) is expected starting mid-2026. Management reiterated, “Our fully enrolled Phase III pivotal program remains on track to deliver top line ...

Operating an in-house durable medical equipment (DME) program can increase both patient satisfaction and profitability. Sustainable, successful programs are built on a solid foundation that includes ...

-- Expansion of end-to-end patient solutions with a customized software & service platform that will help increase compliance, optimize workflow, and maximize ...

Senate leaders have joined colleagues in the the House in sponsoring a bill that would delay a Medicare program calling for competitive billing on durable medical equipment. As things stand, the first ...